WILMINGTON, Delaware, December 16 /PRNewswire/ -- While many of the pharma companies are struggling to outsource their accurate forecast models for new and inmarket drugs, MarketsandMarkets on the other hand provides integrated patient-based forecast solutions to various players. These pharma forecasting solutions are designed for phase I, phase II, as well as phase III. These have a substantial impact on pricing, launch, product life cycle management, market entry strategy, manufacturing planning, sales force, promotion, and planning. The leading pharma companies now endorse the forecast solution provided by MarketsandMarkets as the accurate forecast model, comprising of significant cost benefit analysis for an annual contract basis. The forecasts are based on epidemiology and actual patients on drugs. The primary and secondary research analytics underlying the forecast include:
- Epidemiology analysis - Treated patients best fit trending - Polypharmacy ratio analysis - Competitive landscape analysis - Analogue analysis for uptake, time to peak, and generic erosion - Conjoint / discrete choice / attribute analysis - Calibration based on actual sales and impact of various events
The treated patient pool potential is determined by prevalence, incidence, diagnosis, treatment, cure, and mortality rate. The treated patient pool is also back-calculated simultaneously from historic and present product sales. Trending and smoothening takes into account seasonality and the impact of other events on sale. The conjoint / discrete choice analysis uses primary research to estimate peak patient share for new products. In absence of primary research due to budget / time constraints, an attribute analysis is done using secondary research and consumer inputs to estimate peak patient share for new products.
The peak patient share calculation mechanism is calibrated based on
Copyright©2009 PR Newswire.
All rights reserved